The Ozempic Effect: Navigating GLP-1 Receptor Agonists and Oral Health in Modern Dental Practice
GLP-1 receptor agonists are reshaping dental practice across Saudi Arabia. Nearly 1 in 5 overweight adults has used semaglutide — mostly for weight loss, without endocrinological oversight. This evidence-graded review separates pharmacovigilance findings from animal models, presents the bidirectional GLP-1/periodontitis biology, and gives clinicians a protocol built on what the evidence actually supports.
Research
Executive Summary GLP-1 receptor agonists (GLP-1 RAs) — semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro) — have transformed the management of obesity and type 2 diabetes across the Arab world. In Saudi Arabia, nearly 1 in 5 overweight adults has used these medications, and most are taking them primarily for weight loss rather than diabetes control. This creates a large and growing population appearing in dental chairs with drug-related oral manifestations that most clinicians are not yet equipped to recognize or manage.
This review synthesizes the peer-reviewed evidence on the bidirectional relationship between GLP-1 RAs and oral health. It is written with explicit evidence-level labelling — distinguishing human pharmacovigilance data from animal models and in vitro findings — so that clinicians can calibrate their clinical decisions accordingly. A practical management protocol is provided, grounded in what the evidence currently supports.
--- 1. The Saudi Context: Why This Matters Now Saudi Arabia carries one of the world's heaviest combined burdens of obesity and type 2 diabetes. National data show that 23.1% of adults live with obesity and 23.1% with diabetes — rates that far exceed the global average of 10.5% for diabetes. Projections suggest obesity prevalence may reach 42.9% by 2026. Into this landscape, GLP-1 RAs have rapidly penetrated.
A cross-sectional study from the Eastern Province reported a lifetime prevalence of 18.2% for GLP-1 RA use among overweight and obese adults, with injectable semaglutide commanding 73.9% of the market. Critically, 72.4% of users were taking semaglutide exclusively for weight loss — not under a diabetes diagnosis. This means many GLP-1 patients presenting to dental clinics are not under endocrinological supervision, may not be counselled on oral side effects, and may not connect their dry mouth or new caries to their medication.
The dentist becomes a clinical safety net for this group. The January 2025 SFDA approval of the first generic semaglutide will accelerate access further. This is a permanent shift, not a trend. --- 2. The Oral Side Effect Profile: What the Evidence Actually Shows Dry mouth and salivary dysfunction — the strongest signal The best-quality human evidence for GLP-1 RA oral side effects comes from pharmacovigilance databases.
A 2025 analysis of the FDA Adverse Event Reporting System (FAERS) covering 9,746 GLP-1 RA-related reports found that semaglutide generated significant disproportionality signals for dry mouth, dysgeusia, and anosmia , while GERD was a significant signal for all GLP-1 RAs studied (1). (Human pharmacovigilance data; disproportionality analyses cannot establish causality, but signal strength is meaningful.) A 2025 narrative review examined the mechanistic basis of these findings (2).
Semaglutide's prolonged albumin binding leads to sustained GLP-1 receptor activation in salivary gland tissue, potentially causing receptor desensitization, β-arrestin-mediated internalization, and reduced gland responsiveness over time. The review also notes that different GLP-1 RAs engage cAMP and β-arrestin pathways differently — meaning not all agents will carry equal hyposalivation risk. (Mechanistic narrative review; no human RCT data on salivary flow as a primary endpoint.) The Saudi-affiliated case series by Mawardi et al.
was the first to formally document semaglutide-associated hyposalivation in a clinical series, reporting measurable salivary flow reductions with symptom onset linked to dose escalation (3). (Human case series; small sample, no control group.) An important preclinical counterpoint: an animal study using exendin-4 in an aging rat hyposalivation model found that GLP-1 receptor activation actually improved salivary secretion and preserved gland architecture (4).
This biological complexity — with prolonged pharmacological agonism potentially causing desensitization — is not yet resolved and should prevent oversimplification in patient counselling. (Animal model; not directly translatable to human pharmacology.) GERD and acid erosion — a real, dose-related concern GI adverse events are among the most consistently documented effects of GLP-1 RAs across human RCTs.
The STEP 8 trial reported GI adverse events in 84.1% of semaglutide users and 82.7% of liraglutide users (5). A FAERS-based pharmacovigilance study of 5,442 cases found 45 GI signal types for semaglutide, with GERD among the highest-signal findings (6). For dentistry, repeated acid exposure causes palatal and posterior occlusal enamel erosion. A systematic review confirmed higher prevalence of dental erosion and caries in GERD patients compared with healthy controls (7).
(SR of human studies; direct causal link between GLP-1-induced GERD and dental erosion is inferred, not yet directly demonstrated in a prospective dental study.) Nutritional depletion and bone metabolism — a plausible concern, not yet established The potent appetite suppression of high-dose GLP-1 RAs raises legitimate concern about micronutrient adequacy with downstream effects on alveolar bone density and wound healing.
A 20-week pilot RCT in older adults (n=20) found no statistically significant differences in whole-body bone mineral density or bone turnover markers between semaglutide and lifestyle-only groups, though the study was underpowered and short-term (8). (Small pilot RCT; insufficient to draw conclusions.) Clinicians should ask about dietary adequacy and protein intake and consider recommending supplementation, but should not present alveolar bone loss as an established semaglutide complication.
--- 3. The Bidirectional Biology: A Story With Two Directions How periodontitis undermines GLP-1 drug efficacy A landmark 2017 study demonstrated that three major periodontal pathogens — Porphyromonas gingivalis , Tannerella forsythia , and Prevotella intermedia — all produce DPP-4-like enzymes capable of cleaving and inactivating GLP-1. Intravenou